ADMA Biologics Reports Strong Q1 Profitability Amidst Flat Revenue, Withdraws Long-Term Guidance
ADMA is trading near its 52-week low of $7.21 (7.1% above the low) on elevated volume (2.0× avg).
Summary
ADMA Biologics reported robust first-quarter profitability and cash flow, driven by ASCENIV growth and improved gross margins, despite flat total revenue and a significant decline in BIVIGAM sales. The company withdrew its long-term guidance, citing evolving competitive dynamics in the plasma-derived therapies market.
Key Events · Earnings and Guidance · ADMA
-
Q1 2026 Financial Results
Reported flat total revenue of $114.5 million year-over-year, but achieved 68% GAAP net income growth to $45.3 million and 22% adjusted net income growth to $40.7 million. Diluted EPS increased to $0.19.
-
Product Performance
ASCENIV revenue grew 28% year-over-year to $97.5 million, while BIVIGAM revenue declined 54% year-over-year to $15.4 million due to increased competitive dynamics in the U.S. plasma-derived therapies market.
-
Guidance Update
Reaffirmed FY 2026 revenue guidance of $530-$560 million and adjusted EBITDA of $265-$300 million, but withdrew previously provided long-term guidance due to evolving competitive dynamics.
-
Operational Strength
Achieved a 71% gross margin, up from 53% in the prior year, and generated $58 million in operating cash flow, highlighting strong operational efficiency and resilience.
Analysis · ADMA · Life Sciences
The filing presents a mixed financial picture for ADMA Biologics. While the company demonstrated strong operational efficiency, achieving significant year-over-year growth in GAAP net income, adjusted net income, and adjusted EBITDA, total revenue remained flat due to competitive pressures impacting BIVIGAM sales. The withdrawal of long-term guidance signals increased uncertainty regarding future market dynamics for plasma-derived therapies, which could weigh on investor sentiment. However, the continued strong performance of ASCENIV, high gross margins, and robust cash generation highlight the company's resilience and ability to adapt to a challenging environment. The successful conclusion of the Audit Committee's review, clearing the company of prior allegations, also removes a potential overhang. Investors should monitor the impact of competitive dynamics on BIVIGAM and the company's ability to sustain ASCENIV's growth trajectory.
At the time of this filing, ADMA was trading at $7.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.21 to $23.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.